Summary Of Significant Accounting Policies (Narrative) (Details)	0 Months Ended	1 Months Ended	3 Months Ended		6 Months Ended							6 Months Ended													0 Months Ended	12 Months Ended				0 Months Ended						0 Months Ended	1 Months Ended		0 Months Ended	1 Months Ended		77 Months Ended		6 Months Ended	77 Months Ended	3 Months Ended
	Oct. 31, 2012 USD ($)	Feb. 28, 2013 USD ($)	Jun. 30, 2014 USD ($) employee	Jun. 30, 2013 USD ($)	Jun. 30, 2014 USD ($) pharmacy employee	Jun. 30, 2013 USD ($)	Dec. 31, 2013 USD ($) employee	Sep. 28, 2012	May 10, 2012	May 29, 2009	Feb. 29, 2008	Jun. 30, 2014 Maximum [Member]	Jun. 30, 2014 Minimum [Member]	Jun. 30, 2014 Acthar [Member]	Jun. 30, 2014 Stock Options [Member] USD ($)	Jun. 30, 2013 Stock Options [Member] USD ($)	Jun. 30, 2014 Restricted Stock Award [Member] USD ($)	Jun. 30, 2013 Restricted Stock Award [Member] USD ($)	Jun. 30, 2014 Performance Shares [Member]	Jun. 30, 2013 Performance Shares [Member]	Jun. 30, 2014 Restricted Stock Units (RSUs) [Member] USD ($)	Jun. 30, 2013 Restricted Stock Units (RSUs) [Member]	Jun. 30, 2014 Customer Concentration Risk [Member] Sales [Member] CuraScript SD [Member]	Jun. 30, 2014 Customer Concentration Risk [Member] Accounts Receivable [Member] CuraScript SD [Member]	Jan. 18, 2013 BioVectra [Member] USD ($)	Dec. 31, 2013 BioVectra [Member] CAD	Jun. 30, 2014 BioVectra [Member] USD ($)	Dec. 31, 2013 BioVectra [Member] USD ($)	Jan. 18, 2013 BioVectra [Member] CAD	Jun. 11, 2013 Synacthen [Member] USD ($)	Jun. 11, 2013 Synacthen [Member] Maximum [Member] USD ($)	Jun. 30, 2014 In Process R&D [Member] Synacthen [Member] USD ($)	Dec. 31, 2013 In Process R&D [Member] Synacthen [Member] USD ($)	Jun. 30, 2014 Probability Weighted Discounted Future Cash Flows [Member] Level 3 [Member] BioVectra [Member] USD ($)	Jun. 30, 2014 Probability Weighted Discounted Future Cash Flows [Member] Level 3 [Member] Synacthen [Member] USD ($)	Jul. 01, 2014 Subsequent Event [Member] USD ($)	Jun. 30, 2011 Glenridge Pharmaceuticals, LLC [Member] principal	Sep. 26, 2012 In re Questcor Securities Litigation [Member] lawsuit	Oct. 04, 2012 In re Questcor Shareholder Derivative Litigation [Member] lawsuit	Mar. 31, 2013 David Taban, et al. v. Questcor Pharmaceuticals, Inc [Member] USD ($)	Sep. 28, 2012 Previous Stock Repurchase Plans [Member]	Jun. 30, 2014 Total Shares Repurchased [Member] Common Stock [Member] USD ($)	Jun. 30, 2014 Outside Stock Repurchase Progam [Member] Common Stock [Member] USD ($)	Jun. 30, 2014 Stock Repurchase Program [Member] Common Stock [Member] USD ($)	Jun. 30, 2014 Stock Repurchase Program [Member] Common Stock [Member] USD ($)	Jun. 30, 2014 Windsor, Nova Scotia Production Facility CAD
Summary Of Significant Accounting Policies [Line Items]
Number of specialty pharmacies that distribute					12
Days after quarter, rebate invoices received												90 days	60 days
Products, shelf life from the date of manufacture, months														18 months
Insurance coverage revert, per depositor					$ 250,000
Percentage of sales/accounts receivable																							93.00%	88.00%
Total depreciation and amortization expense					3,200,000	2,800,000
Property, plant and equipment, gross			47,841,000		47,841,000		40,104,000																				32,900,000
Average contractual maturity of short-term investments, in months					15 months
Percentage of voting interest acquired																													100.00%
Total cash paid for acquisition of BioVectra						50,803,000																			50,315,000																					2,400,000
Maximum additional cash consideration																													50,000,000
Number of years financial results are based on																									3 years
Estimated fair value of contingent consideration						30,383,000																			30,383,000
Additional cash consideration paid																										5,000,000
Upfront consideration paid																														60,000,000
Annual cash payments																														25,000,000
Annual payments secured by a letter of credit																														75,000,000
Total payment																															300,000,000
Acquired intangible, net			28,589,000		28,589,000		30,131,000																				28,589,000	30,131,000				186,530,000	191,451,000
Contingent consideration estimate																																		34,766,000	72,011,000
Number of defendants																																					3
Number of plaintiffs																																						4	5
Damages sought																																								5,000,000
Stock repurchase program, number of shares authorized to be repurchased								7,000,000	5,000,000	6,500,000	7,000,000																														3,200,000
Payments for repurchase of common stock					2,146,000	0																																				395,500,000	30,300,000	2,100,000	365,100,000
Repurchase of common stock, shares																																												23,552	17,000,000
Shares of common stock repurchased			0		0																																					23,100,000	6,200,000
Common stock acquired, average cost per share																																										$ 17.09	$ 4.93		$ 21.50
Remaining number of shares authorized to be repurchased																																												5,300,000	5,300,000
Number of employees			528		528		425
Options granted to purchase shares															14,150	343,623
Weighted average exercise price of options granted															$ 54.22	$ 30.06
Award issued, shares																	600,221	731,916	141,500	194,750
Vesting percentage																			40.00%
Share-based compensation cost			$ 8,773,000	$ 6,531,000	$ 17,469,000	$ 12,679,000									$ 5,300,000	$ 5,600,000	$ 11,200,000	$ 5,400,000			$ 241,920
Grants in period																					18,155	0
Dividends declared per share of common stock	$ 0.20	$ 0.20	$ 0.3	$ 0.25	$ 0.6	$ 0.50																														$ 0.30
Number of month expected to retrofit production facility for specialized pharmaceutical fermentation and synthetic organic chemistry products					18 months